Advances in the Research of Diabetic Retinopathy

78.5K
views
147
authors
20
articles
Cover image for research topic "Advances in the Research of Diabetic Retinopathy"
Editors
3
Impact
Loading...
Exosomes are synthesized in various cells. Under physiological or pathological conditions, their carriers may change and participate in the formation of the collective pathological state. They may activate TGF-β, the signaling pathway that mediates the hemodynamics of individuals with PDR. By blocking TGF-β, the activation of the signaling pathway promotes cell proliferation and reduces apoptosis and the inflammatory response. Exosomes (such as miR-141-3p) may also inhibit retinal neovascularization by preventing the activation of the p38/MAPK signaling pathway. Exosomes can also be detected by the PI3K/Akt signaling pathway, which can induce vascular endothelial cell proliferation while preventing cell apoptosis, as well as cell proliferation and migration of the retinal pigment epithelium cell. The stimulation of the signaling system may also aid in the reduction of HG-induced cell proliferation, migration, and angiogenesis. In diabetic rats, the activity of the NF-κB signaling pathway rose dramatically, and inhibiting the NF-κB signaling pathway can reduce inflammation, apoptosis, and oxidative stress.
7,166 views
21 citations
6,710 views
9 citations
Systematic Review
22 June 2022
Meta-Analysis of Relationship of Sleep Quality and Duration With Risk of Diabetic Retinopathy
Zhenzhen Zheng
11 more and 
Riken Chen
Article Cover Image

Objective: A meta-analysis is used to explore the relationship of sleep quality and duration with the risk of diabetic retinopathy (DR).

Method: Cochrane Library, PubMed, Embase, and other databases are searched from their establishment to April 2022. Literature on the relationship of sleep quality and duration with DR risk published in various databases is collected, and two researchers independently screen the literature, extract data, and evaluate the quality of the included articles. The meta-analysis is performed with Review Manage 5.4.1 software.

Results: A total of 7 articles are selected, including 4,626 subjects. The results show a strong correlation between sleep quality and DR risk. When comparing the sleep quality scores of “DR” (experimental group) and “NO DR” (control group), the Pittsburgh sleep quality index(PSQI) score of the DR group is significantly higher than that of the NO DR group (MD = 2.85; 95% confidence interval [CI] 1.92, 3.78, P<0.001), while the ESS score of the DR group is also significantly higher than that of the NO DR group (MD = 1.17; 95% confidence interval [CI] 0.14 to 2.30, P=0.04), so the sleep quality score of the DR group is higher than that of the NO DR group in both the PSQI and ESS scores, which confirms that low sleep quality is a risk factor for DR. Long sleep duration is also associated with the risk of developing DR; the number of adverse events (DR prevalence) is higher for “long sleep duration” than “normal sleep duration” [OR = 1.83, 95%CI 1.36–2.47, P < 0.001], suggesting that long sleep duration can cause increased DR risk. Short sleep duration is also associated with the occurrence of DR [OR = 1.49, 95%CI 1.15–1.94), P = 0.003] and can increase DR risk.

Conclusion: Sleep quality and duration (including long and short sleep duration) are significantly associated with DR. To reduce DR risk, sleep intervention should be actively carried out, lifestyle changes should be made, and attention should be paid to the role of DR management.

4,923 views
11 citations
7,825 views
32 citations
Article Cover Image
Original Research
17 May 2022

Objective: To construct and validate prediction models for the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus.

Methods: Patients with type 2 diabetes mellitus hospitalized over the period between January 2010 and September 2018 were retrospectively collected. Eighteen baseline demographic and clinical characteristics were used as predictors to train five machine-learning models. The model that showed favorable predictive efficacy was evaluated at annual follow-ups. Multi-point data of the patients in the test set were utilized to further evaluate the model’s performance. We also assessed the relative prognostic importance of the selected risk factors for DR outcomes.

Results: Of 7943 collected patients, 1692 (21.30%) developed DR during follow-up. Among the five models, the XGBoost model achieved the highest predictive performance with an AUC, accuracy, sensitivity, and specificity of 0.803, 88.9%, 74.0%, and 81.1%, respectively. The XGBoost model’s AUCs in the different follow-up periods were 0.834 to 0.966. In addition to the classical risk factors of DR, serum uric acid (SUA), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), estimated glomerular filtration rate (eGFR), and triglyceride (TG) were also identified to be important and strong predictors for the disease. Compared with the clinical diagnosis method of DR, the XGBoost model achieved an average of 2.895 years prior to the first diagnosis.

Conclusion: The proposed model achieved high performance in predicting the risk of DR among patients with type 2 diabetes mellitus at each time point. This study established the potential of the XGBoost model to facilitate clinicians in identifying high-risk patients and making type 2 diabetes management-related decisions.

6,063 views
37 citations
Article Cover Image
Original Research
07 April 2022

With increasing incidence of diabetes worldwide, there is an ever-expanding number of patients with chronic diabetic complications such as diabetic retinopathy (DR), one of the leading causes of blindness in the working age population. Early screening for the onset and severity of DR is essential for timely intervention. With recent advancements in genomic technologies, epigenetic alterations in DR are beginning to unravel. Long non-coding RNAs (lncRNAs), which are key epigenetic mediators, have demonstrated implications in several (DR) related processes. Based on the previous research, we have developed a serum-based, multi-panel PCR test using 9 lncRNAs (ANRIL, MALAT1, WISPER, ZFAS1, H19, HOTAIR, HULC, MEG3, and MIAT) to identify and validate whether this panel could be used as a diagnostic and prognostic tool for DR. We initially used a cell culture model (human retinal endothelial cells) and confirmed that 25 mM glucose induces upregulations of ANRIL, HOTAIR, HULC, MALAT1, and ZFAS1, and downregulation of H19 compared to 5 mM glucose controls. Then as an initial proof-of-concept, we tested vitreous humor and serum samples from a small cohort of non-diabetic (N=10) and diabetic patients with proliferative retinopathy (PDR, N=11) and measured the levels of the 9 lncRNAs. Differential expressions of lncRNAs were found in the vitreous and serum of patients and showed significant correlations. We expanded our approach and assessed the same lncRNAs using samples from a larger cohort of diabetic (n= 59; M/F:44/15) and non-diabetic patients (n= 11; M/F:4/7). Significant increased lncRNA expressions of ANRIL, H19, HOTAIR, HULC, MIAT, WISPER and ZFAS1 were observed in the serum of diabetic patients (with varying stages of DR) compared to non-diabetics. No significant correlations were demonstrated between lncRNA expressions and creatinine or glycated hemoglobin (HbA1C) levels. Using ROC and further analyses, we identified distinct lncRNA phenotype combinations, which may be used to identify patients with DR. Data from this study indicate that a panel of serum lncRNAs may be used for a potential screening test for DR. Further large-scale studies are needed to validate this notion.

3,831 views
31 citations

Objective: To compare the efficacy and safety of panretinal photocoagulation (PRP) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) against PRP monotherapy for diabetic retinopathy (DR).

Methods: We searched Pubmed, Cochrane Library, Web of Science, Embase, and Science Direct Register of Controlled Trials from April 2011 to January 2021 to identify the randomized trials that compared the efficacy and safety between PRP combined with intravitreal anti-VEGF and PRP monotherapy for DR. We searched in the following databases between April 2011 and January 2021: Pubmed, Cochrane Library, Web of Science, Embase, and Science Direct without any restriction of countries or article type. The outcome measures were the best-corrected visual acuity (BCVA), neovascularization on the disc (NVD), neovascularization elsewhere (NVE), central macula thickness (CMT), and total retinal volume over time (FAS), and we also observed the adverse events (AEs) between the two groups.

Results: A total of 351 studies were identified, of which 11 studies were included in this meta-analysis (N = 1,182 eyes). Compared with PRP monotherapy, PRP plus anti-VEGF combination treatment produced a mean reduction in BCVA in units of logMAR of -0.23 [95% CI -0.32, -0.15] or a mean improvement in BCVA in units of letters of 4.99 [95% CI 3.79, 6.19], and also yielded a mean reduction in NVD of -28.41 [95% CI -30.30, -26.52], in NVE of -1.33 [95% CI -1.52, -1.14], in CMT of -1.33 [95% CI -1.52, -1.14], or in total FAS. No significant difference was observed on the risk of AEs as vitreous hemorrhage, elevation in intraocular pressure, and cataract between the two different treatments.

Conclusion: PRP with anti-VEGF combination treatment can achieve the ideal efficacy on DR by improving BCVA and NV regression, with no potential increased incidence of AEs, which proves that the combination therapy is an efficient therapeutic strategy that could improve the management of patients with DR.

4,106 views
19 citations
Article Cover Image
6,190 views
35 citations
Fetching...
Open for submission
Frontiers Logo

Frontiers in Immunology

Immune Checkpoint Molecules and Cancer Immunotherapy
Edited by Alexandr Bazhin, Svetlana Karakhanova, Amedeo Amedei
177.1K
views
98
authors
16
articles
Recommended Research Topics
Frontiers Logo

Frontiers in Immunology

Immune Checkpoint Molecules and Cancer Immunotherapy
Edited by Alexandr Bazhin, Svetlana Karakhanova, Amedeo Amedei
177.1K
views
98
authors
16
articles
Frontiers Logo

Frontiers in Immunology

Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer, Colon Cancer and Esophageal Cancer
Edited by Xuelei Ma, Hubing Shi, Udo S Gaipl, Benjamin Frey
319.2K
views
396
authors
48
articles
99.3K
views
177
authors
19
articles
Frontiers Logo

Frontiers in Immunology

Immunotherapy in Small Cell Lung Cancer
Edited by Alfredo Addeo, Alessandro Russo, JANAKIRAMAN SUBRAMANIAN
16.2K
views
64
authors
5
articles
Frontiers Logo

Frontiers in Immunology

Immunologic Tumor Microenvironment Modulators for Turning "Cold" Tumors to "Hot" Tumors
Edited by Mazdak Ganjalikhani Hakemi, Gulderen Yanikkaya Demirel, Chengwu Zeng, Xin He
63.2K
views
107
authors
15
articles